AngioDynamics (ANGO) Investor Update summary

Strategic transformation and market focus

• Shifted to a focused MedTech strategy targeting cardiovascular disease and cancer, emphasizing innovative technologies and measurable patient outcomes.

• Divested non-strategic businesses and invested in differentiated technologies and R&D to drive growth opportunities.

• Expanded Med Tech portfolio, entering mechanical thrombectomy and prostate focal therapy markets, increasing global TAM from $3B in FY2021 to $10B in FY2024.

• Entered larger, faster-growing markets with three core platforms: Auryon (laser for arterial blockages), AngioVac/AlphaVac (thrombectomy systems), and NanoKnife (IRE technology for prostate tumors).

• Recapitalized balance sheet to support margin expansion and sustained profitable growth.

NanoKnife System: Technology, innovation, and clinical validation

• NanoKnife is the first FDA-cleared, non-thermal, radiation-free ablation technology for prostate, offering a function-preserving, hour-long treatment.

• Robust IP and over 2,600 patients treated in 32 peer-reviewed studies support NanoKnife’s clinical positioning.

• Its unique IRE mechanism destroys cancer cells while preserving tissue structure, enabling treatment across all prostate segments, including challenging anatomical areas.

• The PRESERVE pivotal study and meta-analyses confirm strong outcomes in urinary continence, erectile function, and tumor control, with the lowest impact on sexual function among focal therapies.

• NanoKnife received a key FDA indication, positioning it as a standard for function-preserving prostate tumor treatment.

Addressing unmet needs in prostate cancer care

• Prostate cancer is the most diagnosed male cancer globally, with 1.5M annual cases and incidence projected to double by 2040, creating a $2.7B addressable market.

• Current standard treatments force trade-offs between quality of life and cancer control, with high rates of erectile dysfunction and incontinence.

• Focal therapy, targeting only the index lesion, offers a middle ground but is underutilized due to fragmented technology and limited access.

• Focal Therapy adoption remains low in the U.S. due to fragmented technologies and complex integration; NanoKnife addresses these barriers with versatility and ease of use.

• Only all-in-one solution enabling efficient treatment of all prostate segments, easy clinical integration, and strong, reproducible outcomes.